I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner Morpho...
2022-06-15 22:37
2372
I-Mab Biopharma and MorphoSys Announce China IND Submission of TJ202/MOR202
SHANGHAI, Aug. 7, 2018 /PRNewswire/ -- On August 8, 2018 Beijing time I-Mab Biopharma ("I-Mab"), aShanghai-based biotech company focused on innovative biologics in oncology and autoimmune disease, and German biopharma company MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) an...
2018-08-08 09:01
1076
